ABSTRACT: Gilts were assigned as controls (CTL, n = 6 ) or received orally 10 mg of bromocriptine thrice daily from d 110 of gestation until farrowing, (BRPP, n = 7), from d 1 to 6 postpartum ( P P ) (BRL1, n = 6), from d 7 to 13 PP (BRL2, n = 7), from d 14 to 20 PP (BRL3, n = 6), or from d 21 to 27 PP (BRL4, n = 6). Weights of pigs were recorded at birth, 24 h later, and on d 7, 14, 21, 28, 31 (weaning), 42, and 56 PP. Jugular blood samples were collected from sows on d 109 of gestation and every other day until farrowing, as well as on d 1, 6, 13, 20, and 27 PP. Behavioral observations of sows and litters were taken every 3 min for a 24-h period beginning 48 h after the onset of the treatments. In experimental sows, bromocriptine induced marked reductions in prolactin levels during treatment ( P < .001). Compared to CTL sows, concentrations of IGF-I were higher at d 21 ( P = .01) and 28 ( P = .003) PP in BRL3 and BRL4 sows, respectively. In bromocriptine-treated sows, weight gain of litters was either drastically reduced or abolished ( P < .001) during the week of treatment. Treatments also altered significantly the suckling behavior of pigs at all stages studied. Therefore, the present results strongly suggest that prolactin is essential for the initiation and the maintenance of milk production in sows. Results also indicate that prolactin does not seem to be involved in the maintenance of lactational anestrus during a 4-wk lactation.
Introduction
Prolactin is undoubtedly an essential hormone for lactogenesis in various species (Tucker, 1985) . There is a major surge of prolactin immediately before parturition in swine (Taverne et al., 1979) , and suppression of this surge by administration of a dopamine receptor agonist ( DA) inhibits subsequent milk secretion (Whitacre and Threlfall, 1981; Taverne et al., 1982) . After lactation is initiated, an important role for prolactin is also suspected (Boyd et al., 1995) . Endogenous prolactin levels in sows were not correlated with pig weight gains (de Passillé et al., 1995) , but exogenous DA given during the first 48 h postpartum suppressed milk production (Smith and Wagner, 1980) . However, bromocriptine had no effect on growth rate or suckling behavior of pigs when given to sows from d 14 to 22 (Bevers et al., 1983) , d 17 to 21 (Mattioli and Seren, 1985) , or d 27 to 40 of lactation (Benjaminsen, 1981 ). Yet, Boyd et al. (1995) reported a 50% reduction in milk yield of sows receiving a DA on d 30 of lactation. No previous studies have systematically abolished prolactin secretion at various stages of lactation. The objectives of the present trial were therefore to determine the importance of prolactin for the initiation and the maintenance of milk production throughout lactation, using a systematic approach.
Materials and Methods

Animals and Treatments. Pregnant Yorkshire ×
Landrace gilts were assigned to the following treatments: 1 ) control ( CTL, n = 6), 2 ) bromocriptine from d 110 of gestation until farrowing ( d 0; BRPP, n = 7), 3 ) bromocriptine from d 1 to 6 postpartum ( BRL1, n = 6), 4 ) bromocriptine from d 7 to 13 postpartum ( BRL2, n = 7), 5 ) bromocriptine from d 14 to 20 postpartum ( BRL3, n = 6), and 6 ) bromocriptine from d 21 to 27 postpartum ( BRL4, n = 6). Ten milligrams (corrected for purity) of bromocriptine (2-bromo-a-ergocryptine [bromocriptine mesylate]; 88% purity; Sigma Chemical, St. Louis, MO) was given orally at 0700, 1600, and 2230 daily during the treatment period. Twice-daily treatments (at 12-h intervals) were initially tried on two sows, with no obvious visual effects on milk production. Treatments were therefore increased to three times daily for the main trial. The bromocriptine was inserted in a capsule, which was mixed in a ball of precreep feed (22% CP); control sows received a ball of feed containing an empty capsule. All animals were previously trained to eat such a ball of feed (with an empty capsule) starting 2 d before the onset of treatment.
Sows were fed 2.2 kg daily of a commercial feed (14% CP, 3,200 kcal/kg DE, .52% lysine) throughout gestation and were fed increasing amounts (500 g/d increase) of a 16% CP diet (3,300 kcal/kg DE, .68% lysine) during lactation, until they were given ad libitum access to feed. If refusals were greater than 10%, the amount of feed given that day was not increased. Feed and water intakes were measured daily throughout the experiment. Water flow meters were used, and to reduce water wastage, water bowls with a float were used instead of nipple waterers. Backfat thickness measured at the last rib by ultrasound (Scanmatic SM-1, Medimatic, Denmark) and BW of sows were recorded at mating, 109 d of gestation, and at weaning on d 31.
Gilts were housed in individual stalls (.6 × 2.1 m ) during gestation and were transferred to raised farrowing crates on d 109 of gestation. Farrowings took place between October 1994 and February 1995. Neonatal pigs were weighed within 12 h after birth and exactly 24 h after the first weighing. They had no access to water during that period so that weight gain was only due to milk intake over 24 h. Litters were then standardized to 9 ± 1 pigs (9.85 ± .13, mean ± SEM), and only sows with at least eight pigs alive at weaning were kept for the study. Sixty gilts were initially selected to obtain 38 sows meeting this criterion. Litters were weighed on d 2, 7, 14, 21, 28, 31, 42, and 56 . For all treatments, the last capsule of bromocriptine was always given at night and the pigs were weighed the next morning after a 30-min separation from their dams. No creep feed was provided before weaning, and the pigs had no access to the sow's feeder. As demonstrated by Noblet and Etienne (1989) , weight gain of the pigs was used as an estimate of milk yield. Animals were cared for according to a recommended code of practice (Agriculture and Agri-Food Canada, 1993) . If no weight gain was noted between the first two weighings for a pig in the BRPP group, it was killed as described in the guidelines from the Canadian Council on Animal Care (1993) . If after cessation of the bromocriptine treatment, while the litter started gaining weight again, a pig lost weight for three consecutive days, or if a pig was inactive and stopped suckling attempts, then that pig was removed from the study for welfare reasons.
After weaning on d 31, pigs remained in the farrowing cages until d 56.
Jugular blood samples were collected from sows by venipuncture on d 107 of gestation and every other day until farrowing, as well as on d 1 after the second weighing of the pigs, 6, 13, 20, and 27 postpartum. Samples were collected between 1000 and 1100. They were put on ice and centrifuged within 20 min for IGF-I, estradiol, and progesterone analyses. Samples collected for the prolactin assay were left at room temperature for 4 h, stored overnight at 4°C, and centrifuged the following day. Prolactin was measured in serum, and IGF-I (EDTA tubes), estradiol, and progesterone (heparinized tubes) were measured in plasma. Sera and plasma samples were frozen at −20°C until they were assayed.
Behavioral Observations. The behavior of sows and pigs from all litters was recorded by video camera for a period of 24 h starting 48 h after the beginning of the bromocriptine treatment. In the BRPP group, the 24-h recording started right after the second weighing of the pigs. The behavior of control sows and pigs was recorded in parallel. A continuous 30-s recording of each litter was taken every 3 min over one 24-h period using the scan-sampling technique. Behavior was scored from the videotapes at the midpoint of each 30-s sample. Data were thus based on an instantaneous scan at 3-min intervals. The behaviors recorded included the suckling behavior of pigs (massaging, sucking, lying at the udder) and the proportion of pigs present at the udder. The posture of the sow was also noted: sitting, standing, lying on the side (teats exposed), or lying on the belly (teats unexposed). Twenty mutually exclusive behavioral categories were created, each one including the posture of the sow and a combination of the behaviors performed by the pigs.
Hormone Assays. Concentrations of IGF-I (Abribat et al., 1993) , prolactin (Robert et al., 1989) and progesterone (Bolamba et al., 1991) were determined according to previously described RIA procedures. The IGF-I was extracted using the formic acid-acetone method. Briefly, 100 mL of plasma was mixed with 50 mL of 8.0 M formic acid (Fisher Scientific, Nepean, Ontario) containing .5% Tween 20 (Sigma Chemical, Mississauga, ON). The mixture was vortexed and heated to 90°C for 30 min. Then, 350 mL of acetone was added, and the mixture was vortexed again and centrifuged at 3,500 × g for 15 min at 4°C. The supernatant was then diluted in RIA buffer (1/150) for IGF-I measurement. This extraction procedure was validated using triplicates of a pool of plasma from 10 lactating sows. Recovery of exogenously added [ 125 I]IGF-I was 75 to 80%. Concentrations of estradiol were established using a validated assay, which was a modification (Guilbault et al., 1988) of the procedure described by Bélanger et al. (1980) . The first antibody in the IGF-I assay and the unlabeled hormone for the prolactin assay were provided through the National Parallelism of a plasma (for IGF-I) or serum (for PRL) pool from lactating sows was demonstrated in 50 to 200 mL of sample. Average recovery, calculated by addition of various doses of unlabeled hormone to 50 mL of a pooled sample, was 87% for IGF-I and 100% for PRL. Sensitivity of the IGF-I and PRL assays were 6 pg and .1 ng per tube, respectively. The intraassay CV were 7.3, 5.2, 3.9, and 5.9% for IGF-I, PRL, progesterone, and estradiol, respectively. The interassay CV were 2.2, 7.7, 3.5, and 2.1% for IGF-I, PRL, progesterone, and estradiol, respectively.
Statistical Analyses. The GLM procedure of SAS (1990) was used for statistical analyses. Individual analyses for each stage of observation were conducted for backfat and body weight of sows. They included the term treatment (the residual error being the error term) with contrasts comparing the controls to each of the treatments. Sows from the BRPP treatment were not included in the analyses at weaning because they were removed from the study on d 2. Analyses on hormonal data, water and feed intake of sows, and postweaning weights of pigs were done for each stage of observation. Two-way analyses of variance with repeated measures on lactational age were also carried out on these variables, as well as on the weekly weight gain of pigs during lactation, using the initial weight at the beginning of each week as a covariate. The analyses of variance included the terms treatment (the error term being sow within treatment) and time (the residual error being the error term). When the treatment × time interaction was significant, contrasts were used to compare the differences between two successive times for each treatment relative to the controls. An analysis on total litter weight gain during an exact period of 24 h after the first weighing postpartum was also done using litter size as a covariate. Hormonal values were corrected with a logarithmic transformation when variances were not homogeneous. Statistical analyses of behavioral data were done on the total incidences (sum over all animals from each treatment) of performance of each behavioral category during the 24-h scan-sampling period. The nonparametric Wilcoxon test was used to test the effect of treatment because the distribution of data was not normal.
Results
Sow Performances. Body weights of sows were similar across treatments at mating (125.9 ± 4.7 kg, least squares mean ± SEM, P > .10) and on d 109 of gestation (195.8 ± 5.5 kg, least squares mean ± SEM, P > .10). However, at weaning, sows from BRL2 (157.0 kg) and BRL3 (155.3 kg) were heavier than control sows (137.1 ± 6.2 kg, least squares mean ± SEM, P < .05), and those from BRL4 had a tendency to be heavier (152.9, P = .08) than controls. Sows from all treatments had similar backfat thicknesses at mating (14.2 ± 1.2 mm, least squares mean ± SEM, P > .10) and on d 109 of gestation (18.0 ± 1.3 mm, least squares mean ± SEM, P > .10). Yet, at weaning, sows from BRL3 had more backfat (16.3 mm) than control sows (11.4 ± 1.3 mm, least squares mean ± SEM, P < .01). Feed and water intake data of sows during lactation are presented in Table 1 . Even though global treatment effects were only seen during wk 3 and 4, water consumption was decreased ( P ≤ .08) during each week that bromocriptine was given, and this effect could last for up to 3 wk following the onset of treatment (Table 1) . There was a time × treatment interaction ( P < .01) on water intake, and the difference between the mean weekly water intake during the treatment week and that of the preceding week was decreased in BRL2 ( P < .01), and was negative in BRL3 ( P > .01) and BRL4 ( P < .05). Feed intake of sows was not significantly altered by treatments.
Hormonal Data. Prolactin concentrations in sows were significantly affected by exogenous bromocriptine treatments (Table 2 ). There were marked differences between CTL and bromocriptine-treated sows at the end of each treatment period ( P < .001; Table 2 ). There was a significant time × treatment interaction, and the differences between the prolactin values before and after each treatment period were affected by bromocriptine ( P < .004). This was also true for the differences between prolactin values at the end of treatments and 1 wk after cessation of treatments ( P < .001). The differences in prolactin concentrations of bromocriptine-treated sows between 1 and 2 wk after the cessation of bromocriptine were similar to those of control sows ( P > .1). It is of interest to note that prolactin concentrations were decreased ( P ≤ .004) as soon as 24 to 48 h after the onset of bromocriptine in the cases of BRPP and BRL1 (data not shown). Also, prolactin concentrations were always back to values similar to that of control sows ( P > .1) 1 wk after cessation of the treatment (Table 2 ). In the case of BRPP, prolactin concentrations were still lower ( P ≤ .001) on the day after farrowing, even though the treatment had stopped. In the case of IGF-I, there were treatment effects on d 20 ( P = .05) and 27 ( P = .008, Table 3 ). Values from sows receiving bromocriptine on wk 3 were higher than those of controls on d 20 ( P = .01) and 27 ( P = .007), and values from sows receiving bromocriptine during wk 4 were higher than those of controls ( P = .003) on d 27. Concentrations of progesterone were low in all groups at any time, thereby showing that none of the sows ovulated during lactation. There were treatment effects on progesterone values for d 13 ( P < .01) and 20 ( P < .05). Compared to CTL sows, progesterone concentrations in BRL2 and BRL3 sows were lower at d 13 and 20, respectively ( P < .01; Table  4 ). Values for estradiol after each period of treatment were not significantly affected by bromocriptine ( P > .05), and there was no treatment × time interaction ( P > .1; data not shown). Concentrations (least squares means ± SEM) for all treatments were 484 ± 59, 956 ± 113, 37.7 ± 7.2, 10.4 ± 1.8, 8.5 ± 1.1, 6.9 ± 1.3, and 6.8 ± 1.1 pg/mL for d 107 and 115 of gestation and d 1, 6, 13, 20 and 27 of lactation, respectively.
Pig Performances. Mortality rates of pigs were unaffected by treatments ( P > .1), except for BRPP where pigs had to be removed from the study and for BRL1 where there were tendencies for more pigs to die between d 2 and 7 (23.3 ± 7.2 vs 3.1 ± 7.2% for controls, P = .06) and d 15 to 21 (22.2 ± 8.0 vs 0 ± 7.3 for controls, P = .05). Mean pig weights (least squares means ± SEM) were similar among treatments ( P > .1) at birth (1.33 ± .07 kg), at 24 h (1.46 ± .07 kg), or on d 2 postpartum (1.60 ± .08 kg). Yet, total litter gain during exactly 24 h following the first weighing postpartum was affected by treatments ( P < .001). In fact, pigs from sows receiving bromocriptine prepartum lost weight and pigs from all other treatments gained weight during the same period ( −1.12 ± .2 kg vs .72 ± .2 kg for controls and .82 ± .2 kg for the mean of BRL1, BRL2, BRL3, and BRL4). Growth curves for pigs from d 2 to 28 of lactation are shown in Figure 1 , with the exception of BRPP pigs, which were removed from the study at that time. There was a treatment × time interaction ( P < .01) for weight gains of pigs; the weight gain of pigs was decreased from d 2 to 7 ( P < .001) for BRL1, from d 7 to 14 ( P < .001) and d 14 to 21 ( P < .05) for BRL2, from d 14 to 21 ( P < .001) for BRL3, and from d 21 to 28 ( P < .001) for BRL4. Postweaning mean pig weights are shown in Table 5 . Significant treatment effects were still seen on d 31 for BRL2, BRL3, and BRL4, on d 42 for BRL2 and BRL3, and on d 56 for BRL2.
Behavioral Data. Treatment with bromocriptine altered the suckling behavior of pigs at all stages of lactation (Table 6 ). Pigs from treated sows spent more time massaging the udder without teat sucking than pigs from control litters. The incidence of massaging was higher even when the udder was unexposed or when the sows were standing or sitting. Consequently, control sows stood ( P < .006) and sat more often ( P < .05) without pigs at the udder than treated sows on d 16 and 23 of lactation (BRL3 and BRL4, respectively). Moreover, pigs from treated sows performed less normal postsucking behavior than control pigs (Table 6 ). The typical pattern of behavior immediately after sucking and milk ingestion is for some pigs to slowly massage the udder while others lie at the udder, with or without a teat in their mouth.
Also, litters from sows treated with bromocriptine before parturition behaved differently from control litters on the day of farrowing. Treated sows, when compared to controls, were more often lying on their sides with no pigs at the udder ( P = .02; data not shown).
Discussion
The present results strongly suggest that prolactin is essential for the initiation and maintenance of milk production throughout a 4-wk lactation in swine. Prolactin concentrations showed the same prepartum peak (Taverne et al., 1979) and the gradual decrease in lactation as reported previously. The inhibition of lactogenesis by suppressing the prepartum peak of prolactin with bromocriptine was anticipated because such results were previously reported (Whitacre and Threlfall, 1981; Taverne et al., 1982 ). Yet, the effects of bromocriptine on galactopoiesis are novel and most interesting because previous trials reported no effects of exogenous bromocriptine on milk production when Table 4 . Concentrations of progesterone (least squares means) in the blood of sows receiving bromocriptine orally (10 mg thrice daily) prepartum (BRPP) or at various weeks of lactation (BRL1 to BRL4 represent weeks 1 to 4, respectively) a Controls. b P < .10 for contrast comparing value to that of CTL. c P < .05 for contrast comparing value to that of CTL. d Sows from that treatment were removed from the study at this stage. e P ≤ .01 for contrast comparing value to that of CTL. Table 5 . Mean postweaning weights of pigs (least squares means) from sows receiving bromocriptine orally (10 mg thrice daily) at various weeks of lactation (BRL1 to BRL4 represent weeks 1 to 4, respectively)
a Controls. b P < .01 for contrast comparing value to that of CTL. c P < .1 for contrast comparing value to that of CTL. given on d 14 to 22 (Bevers et al., 1983) , 17 to 21 (Mattioli and Seren, 1985) , or 27 to 40 of lactation (Benjaminsen, 1981) . The major difference between these trials and the present one is the frequency of administration of bromocriptine; it was given twice daily in previous trials and thrice daily in our experiment. Even though the concentrations of prolactin were decreased with the twice-daily administration (Benjaminsen, 1981; Bevers et al., 1983; Mattioli and Seren, 1985) , this frequency of treatment was most likely inadequate to lower these concentrations for a long enough period of time to have biological effects. Accordingly, Benjaminsen (1981) stated that the dosage chosen in their experiment may have been low because some elevated prolactin values were found during treatment. Another piece of evidence supporting that prolactin supports galactopoiesis is that when ergocryptine (another DA) was infused i.v. to sows during the first 48 h following parturition at a rate of .05 mg·kg −1 ·24 h −1 , which is equivalent to 7 to 8 mg/d, milk production of sows was suppressed (Smith and Wagner, 1980) . A similar infusion given to two sows during lactation ( d 5 to 20) decreased prolactin concentrations to less than 1 ng/mL and markedly reduced pig growth rate during the 24-h treatment period (Wagner et al., 1983) . Similarly, two intramuscular injections of lergotrile mesylate ( a DA) given on d 30 of lactation inhibited prolactin secretion and reduced milk yield by half in two sows (Boyd et al., 1995) . Bromocriptine given i.m. was effective in inhibiting lactation dose-dependently in the presence of continuous stimulation by the pigs (Fluckiger, 1972) , but the stage of the lactation cycle was not reported. It is also of interest to note that when bromocriptine was injected s.c. to lactating sows, serum concentrations of prolactin were decreased for a 24-h period (Kraeling et al., 1982) . The mode of administration of the DA therefore seems to be important for its biological potency. Table 6 . Total incidences of suckling behaviors for pigs from sows receiving bromocriptine (B) orally (10 mg thrice daily) prepartum (BRPP) or at various weeks of lactation (BRL1 to BRL4 represent weeks 1 to 4, respectively) as compared to behaviors of pigs from control sows (C) at the same periods of lactation a a Total frequency of behavior for the six C and six B sows over the 24-h scan-sampling periods. An interesting fact is that the twice-daily treatment with bromocriptine suppressed lactogenesis when given prepartum (Taverne et al., 1982) . It is therefore apparent that the frequency of administration of DA is not as critical when attempting to inhibit the onset of milk production as compared to the maintenance of milk production.
The growth rates of pigs and the behavioral measurements indicated an inhibition of milk production with bromocriptine. There was either a very marginal or absolutely no weight gain during the week of treatment. Accordingly, pigs from sows receiving bromocriptine showed much greater attempts to obtain milk from their dams. On the other hand, pigs from sows whose lactogenesis was inhibited practically gave up trying to get milk and just lay away from the sow's udder. One cannot exclude the possibility that bromocriptine administered to the dam would be present in milk and, therefore, ingested by the pigs. This could bring about nausea, vomiting, dizziness, and diarrhea, which are common sideeffects of bromocriptine in humans (Council of the Royal Pharmaceutical Society of Great Britain, 1993 ). Yet, pigs were observed thrice daily, and there seemed to be no indications of such ill-effects during the treatment periods.
The decreased water intake of sows during the week of bromocriptine treatments is also indicative of a reduced milk production, and this effect always persisted for weeks after the end of the treatment period. The difference in weight between pigs from treated and control sows was still significant on d 56 for BRL2 and on d 42 for BRL2 and BRL3. Therefore, even though the concentrations of prolactin were back to normal values at the end of the week posttreatment, milk production might still have been impaired.
The greater IGF-I concentrations seen with bromocriptine treatments given in later lactation (wk 3 or 4 ) likely reflected a more positive energy balance in those sows (Weller et al., 1994) , because feed consumption is maximal at that time and milk production was decreased. This was corroborated by the greater body weight at weaning in sows from those treatments when compared to controls.
A lack of effect of bromocriptine on estradiol values in sows was also reported by Taverne et al. (1982) , when given prepartum, or by Mattioli and Seren (1985) , when given in late lactation. Previous reports showed no effect of bromocriptine on progesterone concentrations when given prepartum (Whitacre and Threlfall, 1981; Taverne et al., 1982) . Yet, when given on d 30 to approximately 40 of lactation, Benjaminsen (1981) noted that 2 of 6 sows had elevated progesterone values. The lower progesterone concentrations observed with BRL1, BRL2, and BRL3 in the present trial were unexpected and, unlike the study from Benjaminsen (1981) , indicate that sows did not form corpora lutea during lactation. This difference might be attributed to the stage of lactation at which the treatment was given. The present results therefore corroborate that prolactin does not seem to suppress ovarian activity during lactation (Mattioli and Seren, 1985) , thereby supporting the essential role of the suckling-induced neuroendocrine reflexes for the inhibition of the hypothalamo-pituitary-ovarian axis during a 4-wk lactation.
Implications
The present results strongly suggest that prolactin has an essential role for both the initiation and maintenance of milk production in sows. Interestingly, this role of prolactin seems as important from the 1st to the 4th wk of lactation, and negative effects following an inhibition of prolactin secretion are still seen for 2 wk or so after cessation of the treatment. These results are important because they shed light on the implication of prolactin for the maintenance of milk production in swine.
